XML 110 R88.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENTED INFORMATION (Disclosure of reportable segments) (Details) - CAD ($)
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disclosure of operating segments [line items]    
External net sales $ 872,495 $ 29,816
Cost of sales 644,610 289,011
Depreciation and amortisation 600,322 613,714
Interest Expense 91,323 107,373
Net loss (10,039,658) (11,703,990)
Segment assets 18,396,185 22,585,056
Segment liabilities 3,646,738 2,411,845
Capital expenditures 184,612 591,956
IP Development [Member]    
Disclosure of operating segments [line items]    
External net sales 79,995 29,816
Cost of sales 578,419 289,011
Depreciation and amortisation 600,322 613,714
Interest Expense 91,323 107,373
Net loss (7,075,798) (8,368,889)
Segment assets 10,013,831 15,217,568
Segment liabilities 2,816,136 2,199,276
Capital expenditures 1,398 320,099
Biotech [Member]    
Disclosure of operating segments [line items]    
External net sales 792,500 0
Cost of sales 66,191 0
Depreciation and amortisation 0 0
Interest Expense 0 0
Net loss (262,462) (951,877)
Segment assets 828,439 8,477
Segment liabilities 238,003 145,833
Capital expenditures 0 0
Albany Project [Member]    
Disclosure of operating segments [line items]    
External net sales 0 0
Cost of sales 0 0
Depreciation and amortisation 0 0
Interest Expense 0 0
Net loss (18,597) (508,773)
Segment assets 7,553,915 7,359,011
Segment liabilities 0 0
Capital expenditures 183,214 271,857
Unallocated Corporate Costs [Member]    
Disclosure of operating segments [line items]    
External net sales 0 0
Cost of sales 0 0
Depreciation and amortisation 0 0
Interest Expense 0 0
Net loss (2,682,801) (1,874,451)
Segment assets 0 0
Segment liabilities 592,599 66,736
Capital expenditures $ 0 $ 0